The clinical relevance between survival and TP53 indicates that Tp53 mutation also negative regulates survival rate of the NSCLC patients with EGFR mutation and a T790M resistance mutation treated with Osimertinib [22]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.